Nexalin Technology, Inc.NXL

Nexalin Technology, Inc. just filed its 10-Q for the quarter ended 31 March 2026, and the headline number-$14,950 in revenue-shrinks the company to the size of a large coffee order at a hospital cafeteria. The statement of operations shows a net loss attributable to the parent of $2.1 million, an operating loss of the same size, and a loss per diluted share of 11 cents. Cash and cash equivalents at quarter-end totalled $1.2 million, while short-term investments added another $1.5 million, producing a combined liquidity cushion that still leaves the group with total assets of $3.7 million against liabilities of $808,364.

What Nexalin does, in theory, is neuromodulation: it sells or leases devices said to use ‘patented, frequency-related, advanced waveforms’ to interact with deep midbrain centres and normalise brain chemistry. On the evidence, the company’s commercial footprint today is indistinguishable from zero: the filing does not disclose a single customer name, unit volume, or revenue by geography or product line. Instead, Nexalin markets itself as a platform play, having acquired in May 2026 an AI-integrated digital health stack called HALO™ Clarity and Nexalin NeuroCare™ that it believes will underpin a future at-home, physician-supervised therapy. Management asserts the acquisition strengthens its ability to integrate device, software, AI-enabled remote monitoring, and clinical-data infrastructure, but the filings provide no evidence of revenue, trials under way, or regulatory submissions beyond a Brazilian study whose lead investigator received a Young Researcher Award at BRAIN 2026 for research into the company’s DIFS™ platform.

The company’s latest DEF 14A lauds Executive Chairman and CEO James White for ‘over twenty-five years in leadership roles spanning medical device development, clinical operations and business development,’ while the balance sheet continues to haemorrhage. Research and development spend was $346,382 in the quarter, up from prior periods, and inventory rose by $48,016 to $179,489. Net cash used in operating activities was $1.7 million, and the weighted average diluted share count for the quarter stood at 19.8 million shares. The Audit Committee Charter, posted on the company’s website, offers the usual promises of rigorous oversight, but the numbers suggest the committee is currently auditioning for a role in a low-budget documentary. There is no disclosure of stock buybacks; dilution via share issuance is the only thing growing faster than the R&D budget.

The company’s public-facing site features product imagery and claims about ‘normalising brain chemicals’ through waveform interaction with deep midbrain centres, while the filings show a company with $1.2 million in cash, $1.5 million in short-term investments, and total assets of $3.7 million. For context on the company’s operating profile and the gap between platform narrative and filed reality, see the Nexalin Technology 10-Q for the period ending 2026-03-31 (SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1527352/000182912626004854/nexalintechno_10q.htm) and the company’s official product page at https://nexalin.com/. The site does not disclose unit sales, customer names, or regulatory approvals beyond the Brazilian clinical trial referenced in the company’s press releases.

What changed this week: Nexalin filed its ARS on 10 July 2026 and its DEF 14A on the same day, both accessible via SEC EDGAR (https://www.sec.gov/Archives/edgar/data/1527352/000182912626007515/nexalintech_ars.pdf and https://www.sec.gov/Archives/edgar/data/1527352/000182912626007513/nexalintech_def14a.htm). The DEF 14A also includes bios for James White and Carolyn Shelton, noting Shelton joined in September 2024 as SVP of Quality, Regulatory and Clinical Affairs. The company’s press-release rail announced on 10 July 2026 that the investigator of its Brazilian clinical trial received the Young Researcher Award at BRAIN 2026 for research evaluating the company’s DIFS™ platform, and on 25 June 2026 the company announced two clinical abstracts accepted for presentation at the 2026 NYC Neuromodulation Conference highlighting preliminary clinical results across anxiety, depression, insomnia and quality of life. None of these disclosures quantify revenue, sales volumes, or regulatory milestones that would convert the narrative into filed financial substance.

What remains unproven: There is still no filed evidence of FDA clearance, CE mark, or other regulatory approvals for any Nexalin device beyond the Brazilian clinical trial referenced in company press releases. The filings do not disclose unit volumes, customer names, contract values, or revenue recognition policies beyond the single quarterly revenue figure. Clinical abstracts accepted for presentation do not constitute peer-reviewed evidence, and the Brazilian trial investigator’s award is a recognition of academic merit, not of device efficacy or commercial readiness. Until the company files a pivotal study protocol, a regulatory submission, or audited revenue disclosures, the platform story and the balance-sheet story remain separate narratives.

The evidence would deepen materially if Nexalin files a pivotal trial protocol with FDA, discloses audited revenue with customer names and unit volumes, or reports positive topline results from a controlled study. Until then, the gap between the polished platform narrative and the filed numbers is the only thing that is demonstrably growing.